Symptomatic hyperlactataemia and lactic acidosis in the era of highly active antiretroviral therapy

South African Medical Journal

Volumn 95, Issue 12 I, 2005, Pages 929-930

  Eshun Wilson, Ingrid ^a   Soentjens, Patrick ^a,b   Zeier, Michele ^a,c   Taljaard, Jantjie ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Adult HIV Research Unit   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIOXIDANT; ANTIRETROVIRUS AGENT; BICARBONATE; BIGUANIDE DERIVATIVE; CARNITINE; CYANIDE; DIDANOSINE; ISONIAZID; LACTIC ACID; LAMIVUDINE; METHANOL; PROTEINASE INHIBITOR; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SALICYLIC ACID DERIVATIVE; STAVUDINE; TENOFOVIR; THIAMINE; VITAMIN; ZIDOVUDINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ARTICLE; CARDIOMYOPATHY; DYSPNEA; FATIGUE; FATTY LIVER; FLUID THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY; MYALGIA; MYOPATHY; NEUROMUSCULAR DISEASE; NEUROPATHY; PANCREATITIS; PROGNOSIS; SYMPTOMATOLOGY; VOMITING; WEIGHT REDUCTION;

ACIDOSIS, LACTIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; LACTIC ACID; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 29644442953     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Arenas-Pinto A, Grant AD, Edwards S, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003; 79: 340-343.
2. McComsey G, Lonergan JT. Mitochondrial dysfunction: Patient monitoring and toxicity management. J Aquir Immune Defic Syndr Hum Retrovirol 2004; 37: S30-S35.
3. Lonergan JT, Barber E, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003; 17: 2495-2499.
4. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodefeciency virus-infected patients: Report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838-946.
5. National Institute of Health. Safety and toxicity of individual antiretroviral agents in pregnancy. Supplement. Safety and Toxicity 2004; 23: 1-7.
6. Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV- infected patients treated with nucleoside reverse-transcriptase inhibitors: A case-control study. Clin Infect Dis 2003; 36: 1324-1328.
7. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18: 137-151.
8. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16: 1341-1349.
9. Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003; 3: 329-37.
10. John M, Moore CB, James IR, et al6. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.
11. Bartlett JG. Medical Management of HIV Infection. Baltimore: Johns Hopkins University School of Medicine, 2004: 91-93.
12. Manfredi R, Motta R, Patroon D, et al. Frequency, risk factors and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy. AIDS 2003; 17: 2131-2133.